Article

5 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    8 5 0 0


Biomedicine and pharmacotherapy
Volume 63, n° 9
pages 635-642 (novembre 2009)
Doi : 10.1016/j.biopha.2009.01.008
Received : 22 December 2008 ;  accepted : 13 January 2009
Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats
 

Keizo Fukushima , Masakazu Shibata, Kazunori Mizuhara, Hiroaki Aoyama, Rie Uchisako, Shinji Kobuchi, Nobuyuki Sugioka, Kanji Takada
Department of Pharmacokinetics, Kyoto Pharmaceutical University, 1 Shichono-cho Misasagi Yamashina-ku, Kyoto 607-8412, Japan 

Corresponding author. Tel.: +81 75 595 4626; fax: +81 75 595 6311.
Abstract

Atazanavir (ATV) has been successfully used in HIV patients with severe hyperlipidemia (HL); however, little is known about the pharmacokinetics of ATV in HL. The aim of this study was to investigate the pharmacokinetics of ATV in HL. With the increase of serum lipids, the protein binding rate in HL rats (approximately 97%) was significantly higher than that in control (approximately 87%). After intravenous (iv), oral (po) and intraportal (ip) administration of ATV at a dosage of 7mg/kg, AUCs in HL rats were 12.41, 5.24 and 8.89μg/mLh, respectively, and were significantly higher than those in control rats (4.09, 1.70 and 3.38μg/mLh). Despite the decrease of distribution volume (Vdss ), the terminal half-life (t1/2 ) in HL tended to be shorter than in control, and hepatic distribution of ATV in HL rats was 4.8-fold increases. These results suggested that the uptake of ATV into liver might counteract the decrease of Vdss . On the other hand, there was no significant difference in bioavailability, and the lymphatic transport to AUC showed no statistical change. In conclusion, although the protein binding rate and AUC were significantly increased, the pharmacokinetics of ATV might be tolerated in HL.

The full text of this article is available in PDF format.

Keywords : HIV, Atazanavir, Pharmacokinetics, Hyperlipidemia




© 2009  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline